Helpdesk

Sales contact

Home > Resources > How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

Last updated: October 24, 2025

In 2020, we implemented a carbon neutral program for all our clinical trials.
Our goal? To reduce project CO2 emissions without impacting cost, quality or timelines.

Subscribe to our newsletter

Kayentis and Ametris join forces to deliver integrated eCOA solution...

Breaking barriers in pediatric clinical trials: perspectives from two expert...

Navigating BYOD in Clinical Research: Insights for Clinical Trial Success

ePRO in early phase oncology trials: A revolution on the...

Patient-Reported Outcomes in early-phase oncology clinical trialsA Stepping Stone to...

Answering the Sustainability Call: Digital Health Technologies and eCOA

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events